・The debate centers on Sellas’ Phase 3 Regal trial, which is testing its immunotherapy Galinpepimut-S (GPS) as a maintenance treatment for AML patients. ・The readout is nearing a key trigger, with ...
In late 2025, SELLAS Life Sciences Group reported encouraging Phase 2 data for SLS009 in combination with azacitidine and venetoclax in relapsed or refractory acute myeloid leukemia and confirmed that ...
Kura Oncology’s latest earnings call struck an upbeat tone, as management spotlighted a swift U.S. launch for newly approved Comzifty, strong payer traction, and a deep pipeline of upcoming clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results